Good Samaritan Society - Battle Lake | |
105 Glenhaven Drive, Battle Lake, Minnesota 56515 | |
(218) 864-5231 | |
Name | Good Samaritan Society - Battle Lake |
---|---|
Location | 105 Glenhaven Drive, Battle Lake, Minnesota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 55 |
Occupancy Rate | 78% |
Medicare ID (CCN) | 245403 |
Legal Business Name | The Evangelical Lutheran Good Samaritan Society |
Ownership Type | Non Profit - Corporation |
NPI Number | 1639153398 |
Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
Doing Business As | GOOD SAMARITAN SOCIETY - BATTLE LAKE |
Address | 105 Glen Haven Dr, Battle Lake, MN 56515 |
Phone Number | 218-864-5231 |
News Archive
Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.
In 2008, Reuben Granich and his colleagues at the World Health Organization published a paper in the medical journal The Lancet that proposed a new strategy for combating HIV in South Africa, a country staggered by the virus, with as much as 18 percent of the population estimated to be infected.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Medicare is reviewing whether seniors should undergo spine surgeries at same-day surgery centers, the government-run health program announced Wednesday, five months after a USA Today Network-Kaiser Health News investigation revealed a spate of patient deaths following the procedures.
Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.
› Verified 2 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.
In 2008, Reuben Granich and his colleagues at the World Health Organization published a paper in the medical journal The Lancet that proposed a new strategy for combating HIV in South Africa, a country staggered by the virus, with as much as 18 percent of the population estimated to be infected.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Medicare is reviewing whether seniors should undergo spine surgeries at same-day surgery centers, the government-run health program announced Wednesday, five months after a USA Today Network-Kaiser Health News investigation revealed a spate of patient deaths following the procedures.
Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.
› Verified 2 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 22.36 | 14.46 |
Percentage of long-stay residents who lose too much weight | 3.11 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.34 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.96 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 6.4 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 9.66 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 19.89 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.5 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 3.53 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 25.55 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 7.14 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 4.55 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.35 | 95.98 |
Percentage of short-stay residents who made improvements in function | 85.7 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.53 | 82.93 |
News Archive
Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.
In 2008, Reuben Granich and his colleagues at the World Health Organization published a paper in the medical journal The Lancet that proposed a new strategy for combating HIV in South Africa, a country staggered by the virus, with as much as 18 percent of the population estimated to be infected.
A project at Queen's University Belfast aiming to develop a new method of making grafted blood vessels more resilient has been awarded a grant of over £145,000 by national charity Heart Research UK.
Medicare is reviewing whether seniors should undergo spine surgeries at same-day surgery centers, the government-run health program announced Wednesday, five months after a USA Today Network-Kaiser Health News investigation revealed a spate of patient deaths following the procedures.
Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.
› Verified 2 days ago
Good Samaritan Society - Battle Lake Location: 105 Glenhaven Drive, Battle Lake, Minnesota 56515 Phone: (218) 864-5231 |